This CME-certified enduring activity is jointly provided by Rutgers Biomedical and Health Sciences and RedMedEd.
RME Hot Seat: Incorporating Personalized Treatment Into Severe Asthma Management
| Overview / Abstract: |
Severe, treatment-resistant asthma continues to be an extreme clinical challenge. An estimated 3%–10% of asthma patients have severe asthma, which is characterized by persistent symptoms, compromised lung function, and a significantly increased frequency and severity of high-risk outcomes. Fortunately, there have been important developments regarding the clinical management of patients with severe asthma. The discovery that severe asthma comprises multiple phenotypes and distinct endotypes linked to differences in airway remodeling and inflammatory pathophysiology has potentially significant implications for managing this patient population. Also, several new tailored biologic therapies have been approved by the US Food and Drug Administration for use in patients with treatment-resistant severe asthma driven by eosinophilic inflammation, with other new treatments in late-stage development. In 2019, the Global Initiative for Asthma (GINA) updated its stepwise treatment guidelines; these guidelines address the use of biologic therapy for patients with severe asthma. In this edition of RME Hot Seat, the members of our expert faculty answer challenging clinical questions on existing and emerging personalized treatment, strategies for implementing the most recent clinical guidelines when choosing optimal treatments for patients with severe asthma, the use of biomarkers to guide diagnosis and therapy, differentiating between severe asthma and poorly controlled asthma, and more. |
|
Expiration |
Oct 08, 2020 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME, Respiratory Therapy CE |
|
Format |
Online |
|
Credits / Hours |
Rutgers Biomedical and Health Sciences designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |
|
Accreditation |
In support of improving patient care, this activity has been planned and implemented by Rutgers Biomedical and Health Sciences and RedMedEd. Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team. |
|
Presenters / Authors / Faculty |
Michael E. Wechsler, MD, MMSc—Program Chair Bradley E. Chipps, MD Flavia C. Hoyte, MD |
|
Activity Specialities / Related Topics |
Internal Medicine, Family Medicine, Asthma |
|
Sponsors / Supporters / Grant Providers |
Support for this activity has been provided through an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. |
|
Keywords / Search Terms |
RedMedEd Asthma, Allergic, Eosinophilic, Neutrophilic. GINA, Phenotype, Endotype, Biomarker, Type 2, Biologic, Anti-IgE, IgE, Anti–IL-5, IL-5, Anti–IL-4, IL-4, personalized, RedMedEd, CME, Free Free CE CME Free CE CME |
|